GenSight Biologics S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GenSight Biologics S.A.
Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.
Renamed Coave Therapeutics Raises $39m To Fund Its Next-Gen Gene Therapies
The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.
Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
EU Review Gets Under Way For Curative Vision Loss Gene Therapy
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.